ver 2.0
View of Long-term cost-effectiveness analysis of onceweekly Semaglutide versus Dulaglutide for the treatment of type 2 diabetes after the renewal of the national drug reimbursement list in China
| Health Decision
https://www.hksmp.com/hdNot validated